Triangle Securities Wealth Management Sells 3,632 Shares of Becton, Dickinson and Company $BDX

Triangle Securities Wealth Management reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 45.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,363 shares of the medical instruments supplier’s stock after selling 3,632 shares during the quarter. Triangle Securities Wealth Management’s holdings in Becton, Dickinson and Company were worth $752,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Saudi Central Bank bought a new position in Becton, Dickinson and Company in the 1st quarter valued at about $26,000. Smallwood Wealth Investment Management LLC bought a new position in Becton, Dickinson and Company in the 1st quarter valued at about $27,000. REAP Financial Group LLC increased its holdings in shares of Becton, Dickinson and Company by 75.3% during the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 55 shares during the period. Alpine Bank Wealth Management bought a new position in shares of Becton, Dickinson and Company during the first quarter worth approximately $29,000. Finally, Cornerstone Planning Group LLC increased its holdings in shares of Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 99 shares during the period. 86.97% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Claire Fraser sold 917 shares of the business’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 2,965 shares of company stock worth $551,536. 0.36% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Wells Fargo & Company raised their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. Citigroup cut shares of Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and lowered their target price for the stock from $217.00 to $185.00 in a report on Thursday, May 22nd. Piper Sandler reaffirmed a “neutral” rating and set a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Barclays lowered their target price on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a report on Tuesday, June 3rd. Finally, Argus lifted their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday. Four research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $213.30.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $188.44 on Friday. The firm has a market cap of $54.01 billion, a PE ratio of 33.89, a price-to-earnings-growth ratio of 1.51 and a beta of 0.27. The firm’s fifty day moving average is $187.42 and its 200-day moving average is $190.65. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.28. The company had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Becton, Dickinson and Company’s revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Sell-side analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company’s payout ratio is 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.